1. Extra-gain of HER2-positive cases through HER2 reassessment in primary and metastatic sites in advanced gastric cancer with initially HER2-negative primary tumours: Results of GASTric cancer HER2 reassessment study 1 (GASTHER1)
   Sook Ryun Park et al, 2016, European Journal of Cancer CrossRef
2. Will molecular target agents enable the multidisciplinary treatment in stage IV gastric cancer?
   Kozo Kataoka et al, 2017, European Journal of Surgical Oncology (EJSO) CrossRef
3. Concordance of HER2 expression in paired primary and metastatic sites of gastric and gastro-oesophageal junction cancers
   Daniel D. Wong et al, 2015, Pathology CrossRef
4. Targeting DNA and mutant p53 by a naphthalimide derivative, NA20, exhibits selective inhibition in gastric tumorigenesis by blocking mutant p53-EGFR signaling pathway
   Guohai Zhang et al, 2020, European Journal of Pharmacology CrossRef
5. Discordance in HER2 Status in Gastro-esophageal Adenocarcinomas: A Systematic Review and Meta-analysis
   A. Creemers et al, 2017, Scientific Reports CrossRef
6. Brain metastases in gastro-oesophageal adenocarcinoma: insights into the role of the human epidermal growth factor receptor 2 (HER2)
   J Feilchenfeldt et al, 2015, British Journal of Cancer CrossRef
7. Conversion Surgery for Patients With Stage IV HER2-Positive Gastric Cancer: A Report of 3 Patients
   Shin Saito et al, 2017, International Surgery CrossRef